Reference

Nitric oxide enhancing antimicrobial compounds, compositions and methods of use

All Rights Reserved. Nitric oxide enhancing antimicrobial compounds, compositions and methods of use. Ellis, James L.; Garvey, David S. (Nitromed, Inc., USA). PCT Int. Appl. WO 2007016677 A2 8 Feb 2007, 79pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. APPLICATION: WO 2006-US30287 2 Aug 2006.In this article, certain chemicals are used. One of their cas registry numbers is 110871-86-8 PRIORITY: US 2005-704426P 2 Aug 2005; US 2005-741455P 2 Dec 2005. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) Section cross-reference(s): 63 The invention describes compns. and kits comprising at least one nitric oxide enhancing group antimicrobial compd., or pharmaceutically acceptable salts thereof, and novel compns. comprising at least one nitric oxide enhancing antimicrobial compd., and, optionally, at least one nitric oxide enhancing compd. and/or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. The antimicrobial compds. of the invention are preferably tobramycin, aztreonam, ciprofloxacin and doripenem. The nitric oxide enhancing antimicrobial compds. are substituted with at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group. The nitric oxide enhancing groups are nitroxides and/or heterocyclic nitric oxide donors. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines. In one embodiment the methods of the invention are for the treatment of bacterial infections assocd. with pulmonary diseases such as cystic fibrosis and for treating Bacillus anthracis infections. .

Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside

All Rights Reserved. Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside. Huynh, Holly K.; Biedenbach, Douglas J.; Jones, Ronald N. (JMI Laboratories, North Liberty, IA 52317, USA). Diagnostic Microbiology and Infectious Disease, 55(3), 241-243 (English) 2006 Elsevier Inc. CODEN: DMIDDZ. ISSN: 0732-8893. DOCUMENT TYPE: Journal CA Section: 10 (Microbial, Algal, and Fungal Biochemistry) Section cross-reference(s): 14 Doripenem (formerly S-4661), a parenteral carbapenem, was tested in combination with an aminoglycoside (gentamicin) to det. the resistance selection of these codrugs during subinhibitory passaging using 6 Pseudomonas aeruginosa isolates.In this article, certain chemicals are used. Some of their cas registry numbers are 83200-96-8 and 148016-81-3 The organisms were selected based on doripenem and gentamicin MIC values to include isolates with MIC values near the susceptible breakpoints of both compds. and 1 strain highly resistant to gentamicin. Baseline MIC values were established for doripenem (2-8 mg/mL) and gentamicin (4 to >256 mg/mL) using ref. broth microdilution methods, and passaging was carried out over 7 consecutive days. Doripenem MIC values increased 2 to 38-fold in 4 isolates, whereas 2 strains maintained the baseline doripenem MIC. When the expt. was performed with doripenem plus gentamicin, 3 strains maintained the original doripenem MIC values, 2 strains had a 2-fold increase, and only 1 strain showed a 4-fold increase in the doripenem MIC values. Previous studies have demonstrated doripenem to be more potent than other members in its class when tested against P. aeruginosa. The combination of doripenem and an aminoglycoside may be an effective treatment of infections caused by P. aeruginosa with elevated carbapenem MIC values with lower risk of selecting further resistance. .